FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma By Ogkologos - January 28, 2026 444 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRANSCEND FL-MZL Cohort Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR A Deep-Learning Model Predicts the Primary System Origin of Malignant Cells... April 26, 2024 Breast Cancer Survivor And Teenage Son Hand-Sew Neck Pillows To Bring... August 15, 2019 FDA Approves Crizotinib for ALK-positive Inflammatory Myofibroblastic Tumour July 25, 2022 Virtual Reality Could Reduce Stress for Chemo Patients, Improving Cancer Outcomes January 23, 2020 Load more HOT NEWS Professor Eithne Costello: On the road to early detection Genetic Testing for Bladder Cancer: What People With Cancer and Their... A Single Colonoscopy Reduces CRC Risk, but Not CRC Mortality Helping Kids with Cancer Speak for the Supportive Care They Need
